Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-26

As I am very much of the cohort for which Viraleze is effective, I am thankful.

I should also observe as a lay person that the human immune system tends to get weaker as we get older, disregarding the effect of various acquired immunities. An example being the prevalence of shingles amongst older people, even amongst the majority who have had chicken pox.

One could therefore make a case for the lack of comparative effectiveness in younger folk being due to their immune systems being more capable of fighting the virus than the older cohort.

My advice to the company would be undertake further limited human clinical trials (they do not have to be huge) to:

1) Verify the preventative effect, in the same way as other prophylactics are being tested. and
2) Further test the treatment effectiveness.

I seriously doubt they will do this. But perhaps they should license the rights to a firm that will.

They should also use these results to bring pressure on the TGA. They will, of course have advised the TGA of these results as part of normal process.